Alnylam Provides Timing for New Pipeline Programs, Inks Two Deals for Biotherapeutics Initiative

After undergoing a makeover of sorts last month when the company unveiled a new product-development strategy, this week it said it remains on track to have five candidates in “advanced” clinical development by 2015.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.